Nandagopal Vrindavanam, MD
Medical Oncology · Bradenton, FLNPI 1912994971
Payments from drug & device makers
Across 123 payments — averaging $932.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$56K
- Genentech, Inc.$36K
- Pfizer$21K
- Novartis$164
- Merck$150
- Amgen$146
- plus $1K from 30 others
What the payments were for
- Consulting fees$1005%
- Food & beverage$1,75790%
- Education$895%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $55,926 |
| Genentech, Inc. | 16 | $35,822 |
| Pfizer | 4 | $21,158 |
| Novartis | 9 | $164 |
| Merck | 9 | $150 |
| Amgen | 6 | $146 |
| Bristol Myers Squibb | 7 | $131 |
| GSK | 2 | $114 |
| Genentech USA, Inc. | 6 | $96 |
| Lilly USA, LLC | 6 | $88 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Eisai Inc. | 4 | $83 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Bayer | 3 | $60 |
| Incyte Corporation | 3 | $48 |
| AMAG Pharmaceuticals, Inc. | 2 | $46 |
| Sanofi | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 3 | $41 |
| Johnson & Johnson | 2 | $36 |
| Foundation Medicine, Inc. | 1 | $36 |
| AbbVie | 2 | $35 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Partner Therapeutics, Inc. | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
How this compares
$114,682 in reported general payments places this provider in the 65th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 38 | $540,190 |
| XtandiEnzalutamide | 27 | $390,995 |
| ImbruvicaIbrutinib | 28 | $312,104 |
| Lenalidomide | 17 | $247,004 |
| ErleadaApalutamide | 13 | $194,290 |
| JakafiRuxolitinib Phosphate | 12 | $138,607 |
| Abiraterone Acetate | 41 | $84,141 |
| EliquisApixaban | 48 | $38,167 |
| CreonLipase/Protease/Amylase | 16 | $36,813 |
| XareltoRivaroxaban | 46 | $35,714 |
| Budesonide EcBudesonide | 11 | $2,737 |
| Hydroxyurea | 65 | $1,178 |
| Imatinib Mesylate | 12 | $900 |
| Anastrozole | 70 | $890 |
| Potassium Chloride | 71 | $890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $55,926 | $540,19038 claims |
| Astellas Pharma US IncXtandi | $17 | $390,99527 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $24 | $312,10428 claims |
| Johnson & JohnsonErleada, Xarelto | $36 | $230,00459 claims |
| Incyte CorporationJakafi | $48 | $138,60712 claims |
| PfizerEliquis | $21,158 | $38,16748 claims |
| AbbVieCreon | $35 | $36,81316 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $19518 claims |
| Lilly USA, LLCOlanzapine | $88 | $11624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Bradenton
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.